Terug
Dagbereik
€ 181,81
€ 188,93
52-Weeksbereik
€ 152,33
€ 246,33
Volume
526.900
50D / 200D Gem.
€ 207,33
/
€ 200,41
Vorige Slotkoers
€ 188,09
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (627 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 7,9 | 0,3 |
| P/B | 1,6 | 2,9 |
| ROE % | 21,4 | 3,7 |
| Net Margin % | 8,6 | 3,8 |
| Rev Growth 5Y % | 8,3 | 10,0 |
| D/E | 0,8 | 0,2 |
Koersdoel Analisten
Hold
€ 245,67
+32.1%
Low: € 219,00
High: € 274,00
Forward K/W
8,0
Forward WPA
€ 23,44
WPA Groei (sch.)
+0,0%
Omzet Sch.
18 B
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2029 |
€ 28,77
€ 27,74 – € 29,24
|
21 B | 4 |
| FY2028 |
€ 28,25
€ 26,68 – € 31,03
|
20 B | 6 |
| FY2027 |
€ 25,57
€ 23,79 – € 28,09
|
19 B | 11 |
Belangrijkste Punten
Revenue grew 8,26% annually over 5 years — modest growth
Earnings grew 30,36% over the past year
ROE of 21,36% indicates high profitability
Generating 849,25M in free cash flow
P/E of 7,94 — trading at a low valuation
PEG of 0,26 suggests growth is underpriced
Groei
Revenue Growth (5Y)
8,26%
Revenue (1Y)9,71%
Earnings (1Y)30,36%
FCF Growth (3Y)27,22%
Kwaliteit
Return on Equity
21,36%
ROIC11,70%
Net Margin8,57%
Op. Margin11,48%
Veiligheid
Debt / Equity
0,76
Current Ratio1,05
Interest Coverage12,68
Waardering
P/E Ratio
7,94
P/B Ratio1,62
EV/EBITDA8,62
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 9,71% | Revenue Growth (3Y) | 10,27% |
| Earnings Growth (1Y) | 30,36% | Earnings Growth (3Y) | 44,02% |
| Revenue Growth (5Y) | 8,26% | Earnings Growth (5Y) | 10,69% |
| Profitability | |||
| Revenue (TTM) | 17,36B | Net Income (TTM) | 1,49B |
| ROE | 21,36% | ROA | 9,33% |
| Gross Margin | 90,45% | Operating Margin | 11,48% |
| Net Margin | 8,57% | Free Cash Flow (TTM) | 849,25M |
| ROIC | 11,70% | FCF Growth (3Y) | 27,22% |
| Safety | |||
| Debt / Equity | 0,76 | Current Ratio | 1,05 |
| Interest Coverage | 12,68 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | 7,94 | P/B Ratio | 1,62 |
| P/S Ratio | 0,68 | PEG Ratio | 0,26 |
| EV/EBITDA | 8,62 | Dividend Yield | 0,00% |
| Market Cap | 11,82B | Enterprise Value | 17,19B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 17,36B | 15,83B | 14,28B | 13,40B | 12,64B |
| Net Income | 1,49B | 1,14B | 717,80M | 675,61M | 991,59M |
| EPS (Diluted) | 23,10 | 16,82 | 10,23 | 9,14 | 11,82 |
| Gross Profit | 15,71B | 14,24B | 12,75B | 11,93B | 11,21B |
| Operating Income | 1,99B | 1,68B | 1,18B | 1,00B | 1,36B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 15,96B | 14,47B | 13,97B | 13,49B | 13,09B |
| Total Liabilities | 8,55B | 7,71B | 7,77B | 7,52B | 6,90B |
| Shareholders' Equity | 7,28B | 6,67B | 6,15B | 5,92B | 6,09B |
| Total Debt | 5,51B | 4,96B | 5,37B | 5,27B | 4,56B |
| Cash & Equivalents | 137,80M | 125,98M | 119,44M | 102,82M | 115,30M |
| Current Assets | 3,41B | 2,82B | 2,81B | 2,54B | 2,26B |
| Current Liabilities | 3,24B | 2,21B | 2,01B | 1,91B | 1,98B |
Strategiescores
This stock passed the criteria for 4 strategies
Score = fit strength (0–100)
Rank = position among all matches
Recente Activiteit
Ingestapt
Contrarian Investing (David Dreman)
Mar 25, 2026
Ingestapt
Balanced Risk
Mar 25, 2026
Ingestapt
Lower Risk
Mar 25, 2026
Ingestapt
Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026